Transcriptome sequencing analysis reveals the molecular regulatory mechanism of myocardial hypertrophy induced by angiotensin II
- 11 September 2024
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 229, 116532
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82072160)
- Natural Science Foundation of Jiangsu Province (BK20232023)
This publication has 26 references indexed in Scilit:
- Diverse biological functions of the renin‐angiotensin systemMedicinal Research Reviews, 2023
- Regulatory mechanism of CaMKII δ mediated by RIPK3 on myocardial fibrosis and reversal effects of RIPK3 inhibitor GSK'872Biomedicine & Pharmacotherapy, 2023
- The pathophysiological role of receptor-interacting protein kinase 3 in cardiovascular diseaseBiomedicine & Pharmacotherapy, 2023
- Diminished arachidonate 5-lipoxygenase perturbs phase separation and transcriptional response of Runx2 to reverse pathological ventricular remodelingEBioMedicine, 2022
- Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathwaysActa Pharmacologica Sinica, 2021
- Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal miceiScience, 2021
- Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac researchMolecular and Cellular Biochemistry, 2016
- Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic heartsInternational Journal of Cardiology, 2014
- Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophyJournal of Molecular and Cellular Cardiology, 2010
- Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in miceJournal of Molecular and Cellular Cardiology, 2010